Acne Vulgaris Market By Treatment 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Acne Vulgaris Market
Acne Vulgaris Market : By Treatment (Adapalene, Tazaroteen, Tretinoin & Isotretinoin, Erythromycin & Clindamycin, Hormonal Agents, Anti-inflammatory, Azelaic acid, Resorcinol, Laser & Light Therapy, Cosmetic Procedures & Acne Scar Treatment)-Forecast(2016-2021)
Report Code : HCR 0108
Updated Date: 08 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Acne Vulgaris– Market Overview
2. Executive Summary
3. Acne Vulgaris – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Acne Vulgaris– Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Acne Vulgaris Market
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Acne Vulgaris Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Acne Vulgaris Market - By Treatment
   6.1. Adapalene
   6.2. Tazaroteen
   6.3. Tretinoin
   6.4. Isotretinoin
   6.5. Erythromycin
   6.6. Clindamycin
   6.7. Hormonal agents
   6.8. Combination medications
   6.9. Anti-inflammatory
   6.10. Azelaic acid
   6.11. Resorcinol
   6.12. Laser and light therapy
   6.13. Cosmetic procedures
   6.14. Acne scar treatments    
7. Acne Vulgaris Market– By Geography:
   7.1. Global Study
   7.2. Americas
      7.2.1. North America
      7.2.2. Brazil
      7.2.3. Argentina
      7.2.4. Others
   7.3. Europe
      7.3.1. U.K.
      7.3.2. France
      7.3.3. Germany
      7.3.4. Others
   7.4. APAC
      7.4.1. China
      7.4.2. Japan
      7.4.3. India
      7.4.4. Others
   7.5. ROW
8. Acne Vulgaris Market Entropy
   8.1. New Product Launches
   8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles
   9.1. Allergan
   9.2. Bayer AG
   9.3. Cipher
   9.4. Galderma S.A
   9.5. Hygeia Laboratories Inc
   9.6. Johnson & Johnson Private Limited.
   9.7. Stiefel Laboratories
   9.8. Valeant Pharmaceutical International Inc.
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Acne vulgaris is a common chronic inflammatory skin disease which normally takes place in the adolescence stage on ones life, closer to puberty. Although acne vulgaris is a skin disease, its onset in teenagers often affects their wellbeing because of the physical changes which take place because of the disease. There are a number of factors which lead to acne vulgaris, of which the four primary factors are excessive sebum production, bacterial growth and colonization, sloughing of keratinocytes and inflammation and immune system response. The lesions which are formed from acne vulgaris can often remain as a scar for the greater part of an individual’s life.

One of the key trends observed in the acne vulgaris treatment market is the use of a combination of products for the treatment such as Ziana and Duac. There are a number of products which are available in the market for the treatment of acne vulgaris, however, not all have been found to be suitable for treatment purposes. There have been cases where certain anti-acne products have caused blood clots due to prolonged use. Such products were banned by the medical associations of the respective countries. The initial and only products which were available for acne vulgaris treatment were various types of creams. Today however, there are alternative treatments such as the use of UV and infrared lights which can be provided by numerous clinics. Another key trend in the market has been the setting up of specific skin clinics for various skin conditions of which acne vulgaris is the most common of the lot.

In terms of geographical distribution, the acne vulgaris market for treatment is dominated by North America further to which it is found to be a common disease in the US particularly. It is estimated that more than 60 million individuals are affected by acne vulgaris in the US. Following North America, Europe is the next largest market for acne vulgaris treatment. The APAC region has just come into the limelight with respect to cosmetic treatments. In this view, the APAC market presents the biggest potential for acne vulgaris companies to penetrate. Emerging economies in the region present the best potential for cosmetic-related treatments, especially countries such as India and China.

Acne Vulgaris Market

In terms treatment the Acne Vulgaris market has been divided into the following Adapalene, Tazaroteen, Tretinoin and Isotretinoin, Erythromycin and Clindamycin, Hormonal agents, combination medications, anti-inflammatory, Azelaic acid, Resorcinol, laser and light therapy, cosmetic procedures and acne scar treatments. The Acne vulgaris market has also been segmented by the following geographies Americas, APAC, Europe and ROW.

Sample Companies Profiled in this Report are: 
  • Allergan
  • Hygeia Laboratories Inc
  • Johnson & Johnson Private Limited.
  • Stiefel Laboratories
  • Valeant Pharmaceutical International Inc.
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports